King Pharmaceuticals

Parent Organization: Pfizer Inc

King Pharmaceuticals (NYSE: KG), the world's 39th largest pharmaceutical company, is based in Bristol, Tennessee. King produces a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals currently operates manufacturing facilities in Bristol, Tennessee, Rochester, Michigan, St. Louis, Missouri, St. Petersburg, Florida, and Middleton, Wisconsin, and they employ approximately 2700 people including a sales force of over 1000 individuals.

Source: Wikipedia

Campaign Finance

$52,700 Given
Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

covers through 2011

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for King Pharmaceuticals Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of King Pharmaceuticals

View all lobbying data for King Pharmaceuticals Sources: Lobbyist Registration Tracker OpenSecrets.org

Regulations

6 Mentions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "King Pharmaceuticals" in public comments on proposed federal regulations.

  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 2 FDA Refuse to Approve King's Remoxy NDA Unless the Conditions Specified in the Petition are Satisfied - CLOSED 2011
    • Toggle 2 FDA Determine whether Chloramphenicol Capsules 250 mg was withdrawn from sale for reasons other than safety or effectiveness and grant permission to relist application number A060851 2011
    • Toggle 1 FTC Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules 2011
    • Toggle 1 FDA Request That the Food and Drug Adminstration Make a Determination That OxyContin (Oxycodone Hydrochloride Extended-Releases) Tablets, 10 mg, 15 mg, 20 mg, 40 mg, 60 mg, 80 mg and 160 mg Withdrawn From Sale for Reasons Other Than Safety or Effectiveness 2011
    • Toggle 1 FDA Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications - CLOSED 2011
    • Toggle 1 FTC Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules 2011